Placebo Part B

DRUG4 trials

Sponsors

Dompé Farmaceutici S.p.A, Ono Pharmaceutical Co. Ltd, AstraZeneca, ImmunAbs Inc.

Conditions

HealthyHealthy ParticipantsMyasthenia GravisOsteoarthritis

Phase 1

Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers

CompletedNCT01744704

Dompé Farmaceutici S.p.AHealthy

Start: 2012-07-31End: 2013-03-31Updated: 2024-04-19

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers

CompletedNCT02454387

Ono Pharmaceutical Co. LtdOsteoarthritis

Start: 2015-05-31End: 2016-04-30Updated: 2016-06-30

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

CompletedNCT06122714

AstraZenecaHealthy Participants

Start: 2023-11-07End: 2024-12-04Updated: 2024-12-13

A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis

RecruitingNCT07250750

ImmunAbs Inc.Myasthenia Gravis

Start: 2026-02-05End: 2028-06-01Target: 96Updated: 2026-02-11

Related Papers

Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial.

2014-06-0164 citations